215 related articles for article (PubMed ID: 26009993)
1. A dominant-negative F-box deleted mutant of E3 ubiquitin ligase, β-TrCP1/FWD1, markedly reduces myeloma cell growth and survival in mice.
Sharma R; Williams PJ; Gupta A; McCluskey B; Bhaskaran S; Muñoz S; Oyajobi BO
Oncotarget; 2015 Aug; 6(25):21589-602. PubMed ID: 26009993
[TBL] [Abstract][Full Text] [Related]
2. Associations among beta-TrCP, an E3 ubiquitin ligase receptor, beta-catenin, and NF-kappaB in colorectal cancer.
Ougolkov A; Zhang B; Yamashita K; Bilim V; Mai M; Fuchs SY; Minamoto T
J Natl Cancer Inst; 2004 Aug; 96(15):1161-70. PubMed ID: 15292388
[TBL] [Abstract][Full Text] [Related]
3. SAG/ROC-SCF beta-TrCP E3 ubiquitin ligase promotes pro-caspase-3 degradation as a mechanism of apoptosis protection.
Tan M; Gallegos JR; Gu Q; Huang Y; Li J; Jin Y; Lu H; Sun Y
Neoplasia; 2006 Dec; 8(12):1042-54. PubMed ID: 17217622
[TBL] [Abstract][Full Text] [Related]
4. Mathematical modelling suggests a differential impact of β-transducin repeat-containing protein paralogues on Wnt/β-catenin signalling dynamics.
Benary U; Kofahl B; Hecht A; Wolf J
FEBS J; 2015 Mar; 282(6):1080-96. PubMed ID: 25601154
[TBL] [Abstract][Full Text] [Related]
5. Persistent stimulation with interleukin-17 desensitizes cells through SCFβ-TrCP-mediated degradation of Act1.
Shi P; Zhu S; Lin Y; Liu Y; Liu Y; Chen Z; Shi Y; Qian Y
Sci Signal; 2011 Nov; 4(197):ra73. PubMed ID: 22045853
[TBL] [Abstract][Full Text] [Related]
6. An F-box protein, FWD1, mediates ubiquitin-dependent proteolysis of beta-catenin.
Kitagawa M; Hatakeyama S; Shirane M; Matsumoto M; Ishida N; Hattori K; Nakamichi I; Kikuchi A; Nakayama K; Nakayama K
EMBO J; 1999 May; 18(9):2401-10. PubMed ID: 10228155
[TBL] [Abstract][Full Text] [Related]
7. The role of [beta]-transducin repeat-containing protein ([beta]-TrCP) in the regulation of NF-[kappa]B in vascular smooth muscle cells.
Wang X; Adhikari N; Li Q; Guan Z; Hall JL
Arterioscler Thromb Vasc Biol; 2004 Jan; 24(1):85-90. PubMed ID: 14592850
[TBL] [Abstract][Full Text] [Related]
8. Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo.
Edwards CM; Edwards JR; Lwin ST; Esparza J; Oyajobi BO; McCluskey B; Munoz S; Grubbs B; Mundy GR
Blood; 2008 Mar; 111(5):2833-42. PubMed ID: 18094333
[TBL] [Abstract][Full Text] [Related]
9. Thiazolidinediones modulate the expression of beta-catenin and other cell-cycle regulatory proteins by targeting the F-box proteins of Skp1-Cul1-F-box protein E3 ubiquitin ligase independently of peroxisome proliferator-activated receptor gamma.
Wei S; Lin LF; Yang CC; Wang YC; Chang GD; Chen H; Chen CS
Mol Pharmacol; 2007 Sep; 72(3):725-33. PubMed ID: 17569795
[TBL] [Abstract][Full Text] [Related]
10. Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo.
Edwards CM; Lwin ST; Fowler JA; Oyajobi BO; Zhuang J; Bates AL; Mundy GR
Am J Hematol; 2009 May; 84(5):268-72. PubMed ID: 19296472
[TBL] [Abstract][Full Text] [Related]
11. Mislocalization of the E3 ligase, β-transducin repeat-containing protein 1 (β-TrCP1), in glioblastoma uncouples negative feedback between the pleckstrin homology domain leucine-rich repeat protein phosphatase 1 (PHLPP1) and Akt.
Warfel NA; Niederst M; Stevens MW; Brennan PM; Frame MC; Newton AC
J Biol Chem; 2011 Jun; 286(22):19777-88. PubMed ID: 21454620
[TBL] [Abstract][Full Text] [Related]
12. Targeting beta-transducin repeat-containing protein E3 ubiquitin ligase augments the effects of antitumor drugs on breast cancer cells.
Tang W; Li Y; Yu D; Thomas-Tikhonenko A; Spiegelman VS; Fuchs SY
Cancer Res; 2005 Mar; 65(5):1904-8. PubMed ID: 15753389
[TBL] [Abstract][Full Text] [Related]
13. The FWD1/beta-TrCP-mediated degradation pathway establishes a 'turning off switch' of a Cdc42 guanine nucleotide exchange factor, FGD1.
Hayakawa M; Kitagawa H; Miyazawa K; Kitagawa M; Kikugawa K
Genes Cells; 2005 Mar; 10(3):241-51. PubMed ID: 15743413
[TBL] [Abstract][Full Text] [Related]
14. TRIB2 inhibits Wnt/β-Catenin/TCF4 signaling through its associated ubiquitin E3 ligases, β-TrCP, COP1 and Smurf1, in liver cancer cells.
Xu S; Tong M; Huang J; Zhang Y; Qiao Y; Weng W; Liu W; Wang J; Sun F
FEBS Lett; 2014 Nov; 588(23):4334-41. PubMed ID: 25311538
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.
Navas TA; Nguyen AN; Hideshima T; Reddy M; Ma JY; Haghnazari E; Henson M; Stebbins EG; Kerr I; O'Young G; Kapoun AM; Chakravarty S; Mavunkel B; Perumattam J; Luedtke G; Dugar S; Medicherla S; Protter AA; Schreiner GF; Anderson KC; Higgins LS
Leukemia; 2006 Jun; 20(6):1017-27. PubMed ID: 16617327
[TBL] [Abstract][Full Text] [Related]
16. Impaired degradation of inhibitory subunit of NF-kappa B (I kappa B) and beta-catenin as a result of targeted disruption of the beta-TrCP1 gene.
Nakayama K; Hatakeyama S; Maruyama S; Kikuchi A; Onoé K; Good RA; Nakayama KI
Proc Natl Acad Sci U S A; 2003 Jul; 100(15):8752-7. PubMed ID: 12843402
[TBL] [Abstract][Full Text] [Related]
17. Regulation of lung cancer cell growth and invasiveness by beta-TRCP.
He N; Li C; Zhang X; Sheng T; Chi S; Chen K; Wang Q; Vertrees R; Logrono R; Xie J
Mol Carcinog; 2005 Jan; 42(1):18-28. PubMed ID: 15536641
[TBL] [Abstract][Full Text] [Related]
18. Combined treatment with a transforming growth factor beta inhibitor (1D11) and bortezomib improves bone architecture in a mouse model of myeloma-induced bone disease.
Nyman JS; Merkel AR; Uppuganti S; Nayak B; Rowland B; Makowski AJ; Oyajobi BO; Sterling JA
Bone; 2016 Oct; 91():81-91. PubMed ID: 27423464
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells.
Zou P; Kawada J; Pesnicak L; Cohen JI
J Virol; 2007 Sep; 81(18):10029-36. PubMed ID: 17626072
[TBL] [Abstract][Full Text] [Related]
20. SAG/RBX2 E3 ligase complexes with UBCH10 and UBE2S E2s to ubiquitylate β-TrCP1 via K11-linkage for degradation.
Kuang P; Tan M; Zhou W; Zhang Q; Sun Y
Sci Rep; 2016 Dec; 6():37441. PubMed ID: 27910872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
